TOP TEN perturbations for 38608_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38608_at
Selected probe(set): 206400_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38608_at (206400_at) across 6674 perturbations tested by GENEVESTIGATOR:

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-7.35742
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

melanoma study 34 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-7.3206863
Number of Samples:40 / 4
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control normal skin tissue
Normal skin tissue.

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):6.5827513
Number of Samples:3 / 2
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (adenosquamous carcinoma; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with adenosquamous carcinoma.

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):5.726631
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

esophageal adenocarcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-5.497958
Number of Samples:20 / 18
Experimental esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):5.36483
Number of Samples:3 / 8
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).
Control esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted).

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)

Relative Expression (log2-ratio):5.337694
Number of Samples:3 / 2
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with mucinous adenocarcinoma, endocervical type.

esophageal squamous cell carcinoma study 1 / esophageal adenocarcinoma study 1

Relative Expression (log2-ratio):5.2741213
Number of Samples:8 / 20
Experimental esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.
Control esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):4.9857826
Number of Samples:3 / 6
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with adenocarcinoma (NOS).

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)

Relative Expression (log2-ratio):4.5541353
Number of Samples:43 / 4
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).

Organism: Homo sapiens
Gene: 38608_at
Selected probe(set): 206400_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38608_at (206400_at) across 6674 perturbations tested by GENEVESTIGATOR:

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-7.35742
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

melanoma study 34 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-7.3206863
Number of Samples:40 / 4
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control normal skin tissue
Normal skin tissue.

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):6.5827513
Number of Samples:3 / 2
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (adenosquamous carcinoma; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with adenosquamous carcinoma.

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):5.726631
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

esophageal adenocarcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-5.497958
Number of Samples:20 / 18
Experimental esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):5.36483
Number of Samples:3 / 8
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).
Control esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted).

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)

Relative Expression (log2-ratio):5.337694
Number of Samples:3 / 2
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with mucinous adenocarcinoma, endocervical type.

esophageal squamous cell carcinoma study 1 / esophageal adenocarcinoma study 1

Relative Expression (log2-ratio):5.2741213
Number of Samples:8 / 20
Experimental esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.
Control esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.

expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):4.9857826
Number of Samples:3 / 6
Experimental expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS).
Control expO cervical cancer study 1 (adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the cervix uteri of patients with adenocarcinoma (NOS).

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)

Relative Expression (log2-ratio):4.5541353
Number of Samples:43 / 4
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).